Constellation Pharmaceuticals Enhances and Expands Phase 2 MANIFEST Study of CPI-0610 in Myelofibrosis
October 10, 2018 16:30 ET
|
Constellation Pharmaceuticals , Inc.
– Amends second-line trial design to stratify for transfusion dependence based on positive preliminary data – – Expands study to include an additional arm evaluating CPI-0610 as first-line therapy in...
Geron Announces Discontinuation of Imetelstat Collaboration by Janssen
September 27, 2018 06:00 ET
|
Geron Corporation
Geron regains global rights to imetelstat programHighlights reported for IMerge and IMbarkGeron plans to initiate the Phase 3 portion of IMergeConference call scheduled for 8:00 a.m. ET today MENLO...
Geron to Provide an Update on the Imetelstat Collaboration with Janssen on September 27, 2018
September 26, 2018 20:30 ET
|
Geron Corporation
MENLO PARK, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will host a conference call to provide an update on the imetelstat collaboration with...
Geron Corporation Reports Second Quarter 2018 Financial Results and Recent Company Events
July 31, 2018 16:07 ET
|
Geron Corporation
MENLO PARK, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the three and six months ended June 30, 2018. Second Quarter and Year to...
Constellation Pharmaceuticals Announces Pricing of Initial Public Offering
July 18, 2018 19:56 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., July 18, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (the “Company”)(Nasdaq:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to...
Geron to Present at the Needham Healthcare Conference
March 21, 2018 07:30 ET
|
Geron Corporation
MENLO PARK, Calif., March 21, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at...
Geron Announces Updates to Imetelstat Clinical Development
July 31, 2017 19:00 ET
|
Geron Corporation
MENLO PARK, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced updates to the clinical development plans for IMerge and IMbark, the ongoing trials of the...
Geron Announces Completion of Second Internal Data Reviews for Imetelstat Trials Being Conducted by Janssen
April 10, 2017 07:30 ET
|
Geron Corporation
Both IMerge and IMbark Continue in Lower Risk Myelodysplastic Syndromes and Relapsed or Refractory Myelofibrosis Conference Call Scheduled for 8:00 a.m. EDT Today, April 10 MENLO PARK, Calif.,...
Geron Corporation Reports Fourth Quarter and Annual 2016 Financial Results
March 01, 2017 16:05 ET
|
Geron Corporation
MENLO PARK, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the fourth quarter and year ended December 31, 2016 and recent events. ...
Geron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting
December 06, 2016 16:01 ET
|
Geron Corporation
MENLO PARK, Calif., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced four presentations of exploratory preclinical and clinical data related to the imetelstat...